Sondaggio del sistema cannabinoide in individui con una storia familiare di psicosi
The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that compared to controls with no family history of psychoses, individuals with a family history of psychoses will have an altered response to THC.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Prima fase 1
Contatti e Sedi
Luoghi di studio
-
-
Connecticut
-
West Haven, Connecticut, Stati Uniti, 06516
- VA Connecticut Healthcare System
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria FHP:
- Exposure to cannabis at least once in their lifetime
- Medically and psychiatrically healthy based on screening
- Having one relative with a confirmed psychotic disorder
Exclusion Criteria FHP:
- Current or lifetime major DSM-IV Axis I disorder
- Current or lifetime treatment (at least 6 months) with psychotropic medications for major psychiatric or neurological illness
- Major or unstable medical illness that might impact safety of the subject in the study
- Cannabis naive
- IQ less than 85
- Less than a high school diploma or its educational equivalent
- Pregnancy or lactation
- Major current or recent (<6 weeks) psychosocial stressors.
Inclusion Criteria FHN :
- Exposure to cannabis at least once in their lifetime
- Medically and psychiatrically healthy based on screening
Exclusion Criteria FHN:
- Having a family member with psychosis
- Current or lifetime major DSM-IV Axis I disorder
- Current or lifetime treatment (at least 6 months) with psychotropic medications for major psychiatric or neurological illness
- Major or unstable medical illness that might impact safety of the subject in the study
- Cannabis naive
- IQ less than 85
- Less than a high school diploma or its educational equivalent
- Pregnancy or lactation
- Major current or recent (<6 weeks) psychosocial stressors.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Altro: No Family History of Psychosis (FHN)
Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions. |
placebo Subjects will receive 0.010mg/kg.
Altri nomi:
Subjects will receive 0.018 mg/kg over 20 minutes.
Altri nomi:
|
|
Sperimentale: Family History of Psychosis (FHP)
Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions. |
placebo Subjects will receive 0.010mg/kg.
Altri nomi:
Subjects will receive 0.018 mg/kg over 20 minutes.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
Lasso di tempo: -30 min from administration of THC
|
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. |
-30 min from administration of THC
|
|
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
Lasso di tempo: +80 min from administration of THC
|
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. |
+80 min from administration of THC
|
|
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
Lasso di tempo: +150 min of administration of THC
|
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. |
+150 min of administration of THC
|
|
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
Lasso di tempo: +240 min of administration of THC
|
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. |
+240 min of administration of THC
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Clinician Administered Dissociative Symptoms Scale (CADSS)
Lasso di tempo: -30 min, +15 min, +80 min, +150 min, +240 min
|
Perceptual alterations will be measured using the CADSS. This is a scale consisting of 19 self-report items and 8 clinician-rated items (0=not at all, 4=extremely). The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment. |
-30 min, +15 min, +80 min, +150 min, +240 min
|
|
Visual Analog Scale (VAS)
Lasso di tempo: -30 min, +15 min, +80 min, +150 min, +240 min
|
Feeling states associated with cannabis intoxication will be measured using a self-reported visual analogue scale of four feeling states ("high", "anxious", "calm and relaxed", and "tired") associated with cannabis effects. Subjects will be asked to score the perceived intensity of these feeling states at that moment on a 11 mm line (0=not at all, 100=extremely). These data will be captured to validate that the experiment is relevant to cannabis effects. |
-30 min, +15 min, +80 min, +150 min, +240 min
|
|
Hopkins Verbal Learning Test (HVLT)
Lasso di tempo: +50 min
|
The HVLT is a 12 word list that is semantically organized. The task consists of 5 trials, an interference list, and free delayed recall and recognition. A different version of the AVLT will be administered on each test day and counterbalanced across subjects. |
+50 min
|
|
Psychotomimetic States Inventory (PSI)
Lasso di tempo: -30 min, +240 min
|
The PSI is a measure of drug induced psychotomimetic states. This self-report scale consists of 28 items rated 0 (not at all) to 3 (extremely) and will facilitate the characterization of a wide range of dissociative/hallucinatory phenomena as well as cognitive disorganization associated with the administration of THC. |
-30 min, +240 min
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Mohini Ranganathan, MD, Yale University
Studiare le date dei record
Studia le date principali
Inizio studio
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 1310012948
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .